ClinicalTrials.gg
CompletedNCT02072200Updated Aug 8, 2016Results posted

Efficacy of Lodotra®(Prednisone) in Reduction of Morning Stiffness Duration(K-IMPROvE)

A Phase 4 interventional study of Lodotra® in Rheumatoid Arthritis, sponsored by Mundipharma Korea Ltd. Completed at 1 site in Korea, Republic of. Open to participants aged 20 Years to 80 Years. Per ClinicalTrials.gov, last updated 2016-08-08.

Sponsored by Mundipharma Korea Ltd (part of Mundipharma) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
147
Allocation
Not applicable
Ages
20 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of — 10 open to participants now, 16 under way, 2 of them phase 3. Arthritis, Rheumatoid · Korea, Republic of.

Enrollment
101st of 155
147 · median 300
Started
2013
with 10 others
Phase 4
20 of 188
none open now
Registered
100th of 188
by date

Among the 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of, this one is the 101st largest by enrollment of the 155 interventional ones that give a count, is one of 11 that started in 2013, is one of 20 in phase 4, and was the 100th registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

10 of the 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of are open now. Recruiting first, the newest first:

5 more — sign in →

All 10 open studies →

A study can be open while its sites in Korea, Republic of have not opened yet or have stopped. Only those recruiting at a site in Korea, Republic of →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 20 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Arthritis, Rheumatoid with a site in Korea, Republic of, or all of them as a file.
02

Study summary

This study is multicenter, Ph IV, single arm, interventional study to assess relative reduction of morning stiffness of Lodotra® in Rheumatoid Arthritis patients.Study medication will start after study visit at baseline (week 0, visit 1) and follow-up visit will be after 2, 6 and 12 weeks after treatment (visit 2,3,4).

Read the detailed description

Test Treatment, Dose, and Mode of Administration:

Starting dose is 10mg, and depending on the clinical symptoms and the patient's response, the initial dose can quickly be reduced to a lower maintenance dose. When changing over from the standard regimen (glucocorticoid administration in the morning) to Lodotra® administered at bedtime (at about 10 pm), the same dose (in mg prednisone equivalent) should be maintained, if the subject has taken stable dose within 30 days. Lodotra® dose cannot exceed more than 10mg.

Lodotra® should be taken at bedtime (at about 10 pm), with or after the evening meal and be swallowed whole with sufficient liquid. If more than 2 - 3 hours have passed since the evening meal, it is recommended to take Lodotra® with a light meal or snack.

Modified-release tablets are not to be broken, divided or chewed.

Treatment procedure:At Visit 1(week 0), subjects who qualify for entry into the study will medicated to Lodotra® starting dose of 10 mg daily. (Written informed consent has to be obtained, and subjects will undergo complete evaluation for study eligibility) No dose increase will be allowed for more than 10mg

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • RA, MS, Safety, Efficacy, MR prednisone
04

Who can participate

Ages eligible
20 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients who are diagnosed more than 3 months
  • Morning stiffness on previous treatment with or without oral (below or equal to 10mg per day, methylprednisolone doses were converted into prednisone doses as follows: prednisone dosed=methylprednisolone dose*1.25), average daily duration of 45 min or more.
  • Average daily maximum pain intensity score (100 mm VAS) of 30mm or more.
  • DAS-ESR ≥3.2
  • On DMARD treatment including MTX for ≥3months and stable treatment dose within the past 30 days. There are no limitations on number of DMARDs treatment.(Except patients who have experience of adverse drug reaction of MTX or difficulty to administer MTX due to disease specific condition.)
  • Able to perform study procedures and given written .
  • Naïve patients with Prednisone MR(Lodotra® ) or patients not treat with Prednisone MR(Lodotra®) within 4 weeks(28days)
  • Subject who keeps to administer study drug at 22±30 daily
  • Subject who provide signed and dated written voluntary informed consent

Exclusion criteria

Exclusion Criteria:

  • Patients who suffers from another disease, which requires treatment during the study period.
  • Synovectomy within 4 months prior to study start.
  • Patients who underwent joint injections on only fingers and wrists(both sides) within 4 weeks prior to first visit. disease which, in the investigator's opinion, would exclude the subject from the study.
  • Significant renal impairment (serum creatinine>2.0mg/dl)
  • Significant hepatic impairment (>3 times the in each site)
  • All for glucocorticoids.(established new osteoporotic fractures history of corticoid psychosis, herpes simplex and herpes zoster, varicella infection)
  • Uncontrolled DM(>8.0)
  • Women of , defined as all women physiologically capable of becoming pregnant. UNLESS they are:

    • women whose career, lifestyle, or sexual orientation precludes intercourse with a male partner
    • women whose partners have been sterilized by vasectomy or other means
    • two methods. The two methods can be a double barrier method or a barrier method plus a hormonal method. Adequate barrier methods of contraception include: diaphragm, condom (by the partner), intrauterine device (copper or hormonal), sponge or spermicide. Hormonal contraceptives include any marketed contraceptive agent that includes an estrogen and/or a progestational agent.
  • Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive urine pregnancy test
  • Participation in another clinical study within the past 30 days
  • Known to prednisone
  • Infection patients without effective antimicrobial and systemic mycosis infection patients(infection might be aggravated due to suppression of immunologic function.)
  • Patients with immunization with within 2 weeks of enrollment or planned during the study
  • Since this drug contains glucose, patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take this drug.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
147 participants (actual)

Study arms

  • Experimental
    Modified release prednisone

    Single arm / Lodotra

    Drug: Lodotra®

Interventions

  • Single arm will be received below oral 10mg tablet daily and maximum 10mg/d depending on the clinical symptoms and the patient's response

    Also known as: Modified Release Prednisone

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Morning Stiffness Duration at Week 12 as Assessed by Patient Diary

    Data for the duration of morning stiffness will be obtained from patient diaries. Duration of morning stiffness will be from wake-up time to time of resolution of morning stiffness. Relative reduction rate of the morning stiffness duration from baseline to Week 12 of the study drug treatment was calculated for this outcome measure.

    Time frame: Baseline and 12 weeks

Secondary outcomes

  1. Change of Baseline Severity of Morning Stiffness at Week 12 Using Visual Analog Scale (VAS) Scale

    The VAS is a 100 mm line ranging from 0 mm (no pain) on the left end and 100 mm (worst pain) on the right end. Subjects marked on the line to indicate their pain severity. The distance in mm was measured from the left end to the subject's marking.

    Time frame: Baseline and 12 weeks

  2. Change of Functional Disability Index of the Korea Health Assessment Questionnaire (KHAQ) From Baseline to Week 12

    Change in KHAQ score from baseline to Week 12 post-treatment: KHAQ is composed of 8 functional disability indices. The scale for each index is from 0 (without any difficulty) to 3 (unable to do). Scores for each disability index were summed to obtain the total score for each subject, ranging between 0 to 24, with higher scores reflecting higher functional disability. The scores were then averaged across all subjects.

    Time frame: 12 weeks

07

Results

Posted Aug 8, 2016

Participant flow

Participant flow — Overall Study
MilestoneModified Release Prednisone
Started147
Completed145
Not completed2

Outcome measures

PrimaryChange From Baseline in Morning Stiffness Duration at Week 12 as Assessed by Patient Diary

Data for the duration of morning stiffness will be obtained from patient diaries. Duration of morning stiffness will be from wake-up time to time of resolution of morning stiffness. Relative reduction rate of the morning stiffness duration from baseline to Week 12 of the study drug treatment was calculated for this outcome measure.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · minutes
Change From Baseline in Morning Stiffness Duration at Week 12 as Assessed by Patient Diary
minutesModified Release Prednisone
Change From Baseline in Morning Stiffness Duration at Week 12 as Assessed by Patient Diary-16.76 ± 3.352
SecondaryChange of Baseline Severity of Morning Stiffness at Week 12 Using Visual Analog Scale (VAS) Scale

The VAS is a 100 mm line ranging from 0 mm (no pain) on the left end and 100 mm (worst pain) on the right end. Subjects marked on the line to indicate their pain severity. The distance in mm was measured from the left end to the subject's marking.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · mm
Change of Baseline Severity of Morning Stiffness at Week 12 Using Visual Analog Scale (VAS) Scale
mmModified Release Prednisone
Change of Baseline Severity of Morning Stiffness at Week 12 Using Visual Analog Scale (VAS) Scale-25.70 ± 25.87
SecondaryChange of Functional Disability Index of the Korea Health Assessment Questionnaire (KHAQ) From Baseline to Week 12

Change in KHAQ score from baseline to Week 12 post-treatment: KHAQ is composed of 8 functional disability indices. The scale for each index is from 0 (without any difficulty) to 3 (unable to do). Scores for each disability index were summed to obtain the total score for each subject, ranging between 0 to 24, with higher scores reflecting higher functional disability. The scores were then averaged across all subjects.

Time frame:
12 weeks
Reported as:
Mean · scores on a scale
Change of Functional Disability Index of the Korea Health Assessment Questionnaire (KHAQ) From Baseline to Week 12
scores on a scaleModified Release Prednisone
Change of Functional Disability Index of the Korea Health Assessment Questionnaire (KHAQ) From Baseline to Week 12-4.76 ± 8.16

Adverse events

Collected over 12 weeks. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Modified Release Prednisone—5/145 (3.4%)51/145 (35.2%)
Most frequent serious events
Most frequent serious events
EventModified Release Prednisone
Herpes zosterInfections and infestations1/145
PneumoniaInfections and infestations1/145
SepsisInfections and infestations1/145
Back painMusculoskeletal and connective tissue disorders1/145
Rotator cuff syndromeMusculoskeletal and connective tissue disorders1/145
Most frequent other events
Showing 10 of 19
Most frequent other events
EventModified Release Prednisone
Diarrhoea, vomiting, constipation, gastric disorder, gastritis, gastrointestinal disorderGastrointestinal disorders8/145
Face edema, edema, pain, pyrexia, oedma peripheralGeneral disorders8/145
NasopharyngitisInfections and infestations6/145
Bronchitis, cellulitis, conjunctivitis, folliculitis, rhinitisInfections and infestations5/145
Joint swelling, musculoskeletal pain, neck pain, pain in extremity, synovial cystMusculoskeletal and connective tissue disorders5/145
DyspepsiaGastrointestinal disorders4/145
Alopecia, onychoclasis, rash, urticariaSkin and subcutaneous tissue disorders4/145
Cataract, dry eye, eyelid edema, vision blurredEye disorders4/145
Abdominal pain upperGastrointestinal disorders3/145
NauseaGastrointestinal disorders3/145

Baseline characteristics

These 145 subjects received at least 1 dose of study drug and completed the study.

Age, Continuous
Age, Continuous(participant)Modified Release Prednisone
Mean55.41 ± 11.79
Sex: Female, Male
Sex: Female, Male(Participants)Modified Release Prednisone
Female113
Male32
Region of Enrollment
Region of Enrollment(participants)Modified Release Prednisone
Korea, Republic of145
08

Study locations

1 site
  • Hallym University Sacred Heart Hospital
    Pyeongchon, Kyungkido, Korea, Republic of
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2013, a primary completion of Apr 2015 and a completion of Apr 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2016, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2014
First posted
Feb 26, 2014
Start
Sep 2013
Primary completionActual
Apr 2015
CompletionActual
Apr 2015
Results first posted
Aug 8, 2016
Last update
Aug 8, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 8, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02072200
Responsible party
Sponsor
First posted
Feb 26, 2014
Start date
Sep 2013
Primary completion
Apr 2015
Completion
Apr 2015
Results posted
Aug 8, 2016
Last update
Aug 8, 2016

Study contacts

Seungjae Hong, PhD
principal investigator · Kyunghee University Hospital

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Prednisone

Start the discussion